Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 5/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17477025 | 0.93 | PDE4B (0.44) | PDE4BMTORPIK3CA | |
| SCHEMBL17476985 | 0.92 | GRIN2B (0.35) | PDE4BGRIN2BALDH1A1PFKFB3GRIN1 | |
| SCHEMBL17477015 | 0.90 | PDE4B (0.39) | PDE4BMTORPIK3CAALDH1A1LMNA | |
| SCHEMBL17477017 | 0.88 | PDE4B (0.39) | PDE4BMTORPIK3CAALDH1A1LMNA | |
| SCHEMBL17476990 | 0.87 | PDE4B (0.38) | PDE4BGRIN2BMTORPIK3CAALDH1A1 | |
| SCHEMBL17476893 | 0.87 | S1PR1 (0.36) | PDE4BGRIN2BMTORPIK3CAALDH1A1 | |
| SCHEMBL17476877 | 0.86 | PDE4B (0.35) | PDE4BGRIN2BALDH1A1PFKFB3GRIN1 | |
| SCHEMBL16179402 | 0.86 | PDE4B (0.38) | PDE4BALDH1A1LMNAHTT | |
| SCHEMBL17476949 | 0.86 | ALDH1A1 (0.33) | PDE4BGRIN2BMTORPIK3CAALDH1A1 | |
| SCHEMBL17477001 | 0.86 | PDE4B (0.43) | PDE4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986600-B1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9527832-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | TYMP, PDE4A, DPYD | PDE4B 4/4885GRIN2B 4072/4885MTOR 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.